Serum markers of vascular inflammation in dyslipemia

Clinica Chimica Acta

Volumn 369, Issue 1, 2006, Pages 1-16

  Francisco, Gemma ^a   Hernández, Cristina ^a   Simó, Rafael ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

C reactive protein; Cell adhesion molecules; Chemokines; Cytokines; Dyslipemia; Humans; Vascular inflammation

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CATHELICIDIN; CD40 ANTIGEN; CD40 LIGAND; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; DEFENSIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 6; MEVINOLIN; MYELOPEROXIDASE; NEOPTERIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; PRAVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BLOOD ANALYSIS; CARDIOVASCULAR RISK; DRUG MECHANISM; DYSLIPIDEMIA; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; LIPID ANALYSIS; NONHUMAN; PLEIOTROPY; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; VASCULAR DISEASE; ANIMAL; BLOOD; PATHOLOGY;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; CYTOKINES; DYSLIPIDEMIAS; HUMANS; INFLAMMATION;

EID: 33746505013     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2005.12.027     Document Type: Review

References (248)

1. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 337 (1997) 1360-1369
2. Ross R. Atherosclerosis-an inflammatory disease. N Eng J Med 340 (1999) 115-126
3. Davignon J., and Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 109 (2004) III27-III32
4. Vapaatalo H., and Mervaala E. Clinically important factors influencing endothelial function. Med Sci Monit 7 (2001) 1075-1085
5. Jonasson L., Holm J., Skalli O., Bondjers G., and Hansson G.K. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 6 (1986) 131-138
6. van der Wal A.C., Das P.K., Bentz van de Berg D., van der Loos C.M., and Becker A.E. Atherosclerotic lesions in humans. In situ immunophenotypic analysis suggesting an immune mediated response. Lab Invest 61 (1989) 166-170
7. Libby P., and Ross R. Cytokines and growth regulatory molecules. In: Fuster V., Ross R., and Topol E.J. (Eds). Atherosclerosis and Coronary Artery Disease vol. 1 (1996), Lippincott-Raven, Philadelphia 585-594
8. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 272 (1997) 20963-20966
9. Seppo L., Karjala K., Nevala R., et al. A long-term fish diet modifies the toxic properties of human partially oxidized LDL on vascular preparations in vitro. J Physiol Pharmacol 51 (2000) 251-265
10. Vidal F., Colome C., Martínez-González J., and Badimon L. Atherogenic concentrations of native low-density lipoproteins down-regulate nitric oxide synthase mRNA and protein levels in endothelial cells. Eur J Biochem 252 (1998) 378-384
11. Chen M., Masaki T., and Sawamura T. Lox-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 95 (2002) 89-100
12. Quinn M.T., Parthasarathy S., Fong L.G., and Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A 84 (1987) 2995-2998
13. Rajavashisth T.B., Andalibi A., Territo M.C., et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low density lipoproteins. Nature 344 (1990) 254-257
14. Leonard E.J., and Yoshimura T. Human monocyte chemoattractant protein-1 [MCP-1]. Immunol Today 11 (1990) 97-101
15. Kunjathoor V.V., Febbraio M., Podrez E.A., et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 277 (2002) 49982-49988
16. Stemme S., Faber B., Holm J., Wiklund O., Witztum J.L., and Hansson G.K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A 92 (1995) 3893-3897
17. Li D., Liu L., Chen H., Sawamura T., and Mehta J.L. LOX-1, an oxidized LDL endothelial receptor, induces CD40/CD40L signaling in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol 23 (2003) 816-821
18. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
19. Mehta J.L., and Li D. Identification, regulation and function of a novel lectin-like oxidized low-density lipoprotein receptor. J Am Coll Cardiol 39 (2002) 1429-1435
20. Kunjathoor V.V., Febbraio M., Podrez E.A., et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 277 (2002) 49982-49988
21. Shashkin P., Dragulev B., and Ley K. Macrophage differentiation to foam cells. Curr Pharm Des 11 (2005) 3061-3072
22. Yoshida H., Kondratenko N., Green S., Steinberg D., and Quehenberger O. Identification of the lectin-like receptor for oxidized low-density lipoprotein in human macrophages and its potential role as a scavenger receptor. Biochem J 334 (1998) 9-13
23. Mazer S.P., and Rabbani L.E. Evidence for C-reactive protein's [CRP] role in vascular disease: atherothrombosis, immunoregulation and CRP. J Thromb Thrombolysis 17 (2004) 95-105
24. Hak A.E., Stehouwer C.D., Bots M.L., et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy middle-aged women. Arterioscler Thromb Vasc Biol 19 (1999) 1986-1991
25. Lemieux I., Pascot A., Prud'homme D., et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 21 (2001) 961-967
26. Francisco G., Hernandez C., Chacon P., Mesa J., and Simo R. Factors influencing CRP levels in the diabetic population. Med Clin (Barc.) 124 (2005) 336-337
27. Kushner I., and Mackiewicz A. Acute phase response: an overview. In: Mackiewicz A., Kushner I., and Baumann H. (Eds). Acute Phase Proteins: Molecular Biology, Biochemistry, and Clinical Application (1993), CRC Press, Boca Raton, FL 4-19
28. Yasojima K., Shwab C., McGeer E.G., and McGeer P.L. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 158 (2001) 1039-1051
29. Verma S., Wang C.H., Li S.H., et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106 (2002) 913-919
30. Pasceri V., Willerson J.T., and Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 (2000) 2165-2168
31. Pasceri V., Cheng J., Willerson J.T., and Yeh E.T. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103 (2001) 2531-2534
32. Zwaka T.P., Hombach V., and Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103 (2001) 1194-1197
33. Szmitko P., Wang C.H., Weisel R., de Almeida J., Anderson T., and Verma S. New markers of inflammation and endothelial cell activation: Part I. Circulation 108 (2003) 1917-1923
34. Wang C.H., Li S.H., Weisel R.D., et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 107 (2003) 1783-1790
35. Torzewski J., Torzewski M., Bowyer D.E., et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 18 (1998) 1386-1892
36. Pepys M.B. CRP or not CRP? That is the question. Arterioscler Thromb Vasc Biol 25 (2005) 1091-1094
37. Taylor K.E., Giddings J.C., and van den Berg C.W. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol 25 (2005) 1225-1230
38. Pepys M.B., Hawkins P.N., Kahan M.C., et al. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res 97 (2005) 97-103
39. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
40. Kuller L.H., Tracy R.P., Shaten J., and Meilahn E.N. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 144 (1996) 537-547
41. Koenig W., Sund M., Frohlich M., et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA [Monitoring Trends and Determinants in Cardiovascular Disease] Augsburg Cohort Study, 1984 to 1992. Circulation 99 (1999) 237-242
42. Tracy R.P., Lemaitre R.N., Psaty B.M., et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 17 (1997) 1121-1127
43. Ridker P.M., Buring J.E., Shih J., Matias M., and Hennekens C.H. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98 (1998) 731-733
44. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97 (1998) 425-428
45. Harris T.B., Ferrucci L., Tracy R.P., et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 106 (1999) 506-512
46. Ridker P.M., Stampfer M.J., and Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein[a], and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285 (2001) 2481-2485
47. Liuzzo G., Biasucci L.M., Gallimore J.R., et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331 (1994) 417-424
48. Morrow D.A., Rifai N., Antman E.M., et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI IIA substudy. Thrombolysis in myocardial infarction. J Am Coll Cardiol 31 (1998) 460-1465
49. Biasucci L.M., Liuzzo G., Grillo R.L., et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 99 (1999) 855-860
50. Toss H., Lindahl B., Siegbahn A., and Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. Circulation 96 (1997) 4204-4210
51. Lindahl B., Toss H., Siegbahn A., Venge P., and Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. N Engl J Med 343 (2000) 1139-1147
52. Haverkate F., Thompson S.G., Pyke S.D., Gallimore J.R., and Pepys M.B. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349 (1997) 462-466
53. Heeschen C., Hamm C.W., Bruemmer J., and Simoons M.L. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 anti-platelet therapy in unstable angina refractory to standard treatment trial. J Am Coll Cardiol 35 (2000) 1535-1542
54. Ridker P.M., Rifai N., Pfeffer M.A., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events [CARE] Investigators. Circulation 98 (1998) 839-844
55. Buffon A., Liuzzo G., Biasucci L.M., et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 34 (1999) 1512-1521
56. Milazzo D., Biasucci L.M., Luciani N., et al. Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events. Am J Cardiol 84 (1999) 459-461 [A9]
57. Chew D.P., Bhatt D.L., Robbins M.A., et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 104 (2001) 992-997
58. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 347 (2002) 1557-1565
59. Albert M., Danielson E., Rifai N., and Ridker P.M. Effect of statin therapy on C-reactive protein levels. The Pravastatin Inflammation/CRP Evaluation [PRINCE]: a randomized trial and cohort study. JAMA 286 (2001) 64-70
60. Jialal I., Stein D., Balis D., Grundy S.M., Adams-Huet B., and Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103 (2001) 1933-1935
61. Ridker P.M., Rifai N., and Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 103 (2001) 1191-1193
62. Ockene I.S., Matthews C.E., Rifai N., Ridker P.M., Reed G., and Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 47 (2001) 444-450
63. Roberts W.L., Moulton L., Law T.C., et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications: Part 2. Clin Chem 47 (2001) 418-425
64. van Lente F. Markers of inflammation as predictors in cardiovascular disease. Clin Chim Acta 293 (2000) 31-52
65. Ridker P.M. Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice. Am Heart Hosp J 2 Suppl 1 (2004) 4-9
66. Ropponen A., Aittomaki K., Tikkanen M.J., and Ylikorkala O. Levels of serum C-reactive protein during oral and transdermal estradiol in postmenopausal women with and without a history of intrahepatic cholestasis of pregnancy. J Clin Endocrinol Metab 90 (2005) 142-146
67. Vlassara H., Cai W., Crandall J., et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A 99 (2002) 15596-15601
68. Roberts W.L., Schwarz E.L., Ayanian S., and Rifai N. Performance characteristics of a point of care C-reactive protein assay. Clin Chim Acta 314 (2001) 255-259
69. Roberts W.L., Moulton L., Law T.C., et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications: Part 2. Clin Chem 47 (2001) 418-425
70. Rothkrantz-Kos S., Schmitz M.P., Bekers O., Menheere P.P., and van Dieijen-Visser M.P. High-sensitivity C-reactive protein methods examined. Clin Chem 48 (2002) 359-362
71. Mosca L. C-reactive protein-to screen or not to screen?. N Engl J Med 347 (2002) 1615-1617
72. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
73. Ferroni P., Basili S., Vieri M., et al. Soluble P-selectin and proinflammatory cytokines in patients with polygenic type IIa hypercholesterolemia. Haemostasis 29 (1999) 277-285
74. Hulthe J., and Fagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines [AIR Study]. Arterioscler Thromb Vasc Biol 22 (2002) 1162-1167
75. Seino Y., Ikeda U., Ikeda M., et al. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine 6 (1994) 87-91
76. Ikeda U., Ikeda M., Seino Y., Takahashi M., Kano S., and Shimada K. Interleukin-6 gene transcripts are expressed in atherosclerotic lesions of genetically hyperlipidemic rabbits. Atherosclerosis 92 (1992) 213-218
77. Yudkin J.S., Kumari M., Humphries S.E., and Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis 148 (2000) 209-214
78. Ikeda U., Ito T., and Shimada K. Interleukin-6 and acute coronary syndrome. Clin Cardiol 24 (2001) 701-704
79. Ridker P.M., Rifai N., Stampfer M.J., and Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000) 1767-1772
80. Yamashita H., Shimada K., Seki E., Mokuno H., and Daida H. Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. Am J Cardiol 91 (2003) 133-136
81. Wang X., Feuerstein G.Z., Gu J.L., Lysko P.G., and Yue T.L. Interleukin-1 beta induces expression of adhesion molecules in human vascular smooth muscle cells and enhances adhesion of leukocytes to smooth muscle cells. Atherosclerosis 115 (1995) 89-98
82. Ng S.B., Tan Y.H., and Guy G.R. Differential induction of the interleukin-6 gene by tumor necrosis factor and interleukin-1. J Biol Chem 269 (1994) 19021-19027
83. Filonzi E.L., Zoellner H., Stanton H., and Hamilton J.A. Cytokine regulation of granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor production in human arterial smooth muscle cells. Atherosclerosis 99 (1993) 241-252
84. Hasdai D., Scheinowitz M., Leibovitz E., Sclarovsky S., Eldar M., and Barak V. Increased serum concentrations of interleukin-1 beta in patients with coronary artery disease. Heart 76 (1996) 24-28
85. Hurme M., and Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 28 (1998) 2598-2602
86. Gabriel A.S., Ahnve S., Wretlind B., and Martinsson A. IL-6 and IL-1 receptor antagonist in stable angina pectoris and relation of IL-6 to clinical findings in acute myocardial infarction. J Intern Med 248 (2000) 61-66
87. Patti G., D'Ambrosio A., and Mega S. Early interleukin-1 receptor antagonist elevation in patients with acute myocardial infarction. J Am Coll Cardiol 43 (2004) 35-38
88. Pereira B.J., King A.J., Falagas M.E., and Dinarello C.A. Interleukin-1 receptor antagonist: an index of dialysis-induced interleukin-1 production. Nephron 67 (1994) 358-361
89. Nakanishi K., Yoshimoto T., Tsutsui H., and Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 19 (2001) 423-474
90. Puren A.J., Fantuzzi G., Gu Y., Su M.S., and Dinarello C.A. Interleukin-18 [INFγ-inducing factor] induces IL-8 and IL-1β via TNFα production from non CD14+ human blood mononuclear cells. J Clin Invest 101 (1998) 711-721
91. Morel J.C., Park C.C., Woods J.M., and Koch A.E. A novel role for interleukin-18 in adhesion molecule induction through NFκB and phosphatidylinositol [PI] 3-kinase-dependent signal transduction pathways. J Biol Chem 276 (2001) 37069-37075
92. Komai-Koma M., Gracie J.A., Wei X.Q., et al. Chemoattraction of human T cells by IL-18. J Immunol 170 (2003) 1084-1090
93. Gerdes N., Sukhova G.K., Libby P., Reynolds R.S., Young J.L., and Schonbeck U. Expression of interleukin [IL]-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells and macrophages: implications for atherogenesis. J Exp Med 195 (2002) 245-257
94. Blankenberg S., Tiret L., Bickel C., et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 106 (2002) 24-30
95. Hotamisligil G.S., Shargill N.S., and Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 (1993) 87-91
96. Ridker P.M., Rifai N., Pfeffer M., Sacks F., Lepages S., and Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 101 (2000) 2149-2153
97. Clausell N., de Lima V.C., Molossi S., et al. Expression of tumor necrosis factor alpha and accumulation of fibronectin in coronary artery restenotic retrieved by atherectomy. Br Heart J 73 (1995) 534-539
98. Rosenson R.S., Tangney C.C., Levine D.M., Parker T.S., and Gordon B.R. Elevated soluble tumor necrosis factor receptor levels in non-obese adults with the atherogenic dyslipoproteinemia. Atherosclerosis 177 (2004) 77-81
99. Baggiolini M., and Dahinden C.A. CC chemokines in allergic inflammation. Immunol Today 15 (1994) 127-133
100. Cushing S.D., Berliner J.A., Valente A.J., et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A 87 (1990) 5134-5138
101. Kowalski J., Okopien B., Madej A., et al. Levels of sICAM-1, sVCAM-1 and MCP-1 in patients with hyperlipoproteinemia IIa and IIb. Int J Clin Pharmacol Ther 39 (2001) 48-52
102. Boring L., Gosling J., Cleary M., and Charo I.F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394 (1998) 894-897
103. Matsumori A., Furukawa Y., Hashimoto T., et al. Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction. J Mol Cell Cardiol 29 (1997) 419-423
104. Nishiyama K., Ogawa H., Yasue H., et al. Simultaneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndromes. Jpn Circ J 62 (1998) 710-712
105. Flower L., Ahuja R.H., Humphries S.E., and Mohamed-Ali V. Effects of sample handling on stability of interleukin 6, tumor necrosis factor-alpha and leptin. Cytokine 12 (2000) 1712-1716
106. Ledur A., Fitting C., David B., Hamberger C., and Cavaillon J.M. Variable estimates of cytokine levels produced by commercial ELISA kids: results using international cytokine standards. J Immunol Methods 186 (1995) 171-179
107. Tedder T.F., Steeber D.A., Chen A., and Engel P. The selectins: vascular adhesion molecules. FASEB J 9 (1995) 866-873
108. Adams D.H., and Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet 343 (1994) 831-836
109. Mayadas T.N., Johnson R.C., Rayburn H., Hynes R.O., and Wagner D.D. Leukocyte rolling and extravasation are severely compromised in P-selectin-deficient mice. Cell 74 (1993) 541-554
110. Nageh M.F., Sandberg E.T., Marotti K.R., et al. Deficiency of inflammatory cell adhesion molecules protects against atherosclerosis in mice. Arterioscler Thromb Vasc Biol 17 (1997) 1517-1520
111. Collins R.G., Velji R., Guevara N.V., Hicks M.J., Chan L., and Beaudet A.L. P-selectin or intercellular adhesion molecule [ICAM]-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med 191 (2000) 189-194
112. Poston R.N., Haskard D.O., Coucher J.R., Gall N.P., and Johnson-Tidey R.R. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol 140 (1992) 665-673
113. De Caterina R., Basta G., Lazzerini G., et al. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol 17 (1997) 2646-2654
114. Ridker P.M., Hennekens C.H., Roitman-Johnson B., Stampfer M.J., and Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 351 (1998) 88-92
115. Hwang S.J., Ballantyne C.M., Sharrett A.R., et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 96 (1997) 4219-4225
116. Blankenberg S., Rupprecht H.J., Bickel C., et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 104 (2001) 1336-1342
117. Ridker P.M., Buring J.E., and Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 103 (2001) 491-495
118. Blann A.D., Tse W., Maxwell S.J., and Waite M.A. Increased levels of soluble adhesion molecule E-selectin in essential hypertension. J Hypertens 12 (1994) 925-928
119. Steiner M., Reinhardt K.M., Krammer B., Ernst M., and Blann A.D. Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thromb Haemost 72 (1994) 979-984
120. Fasching P., Veitl M., Rohac M., et al. Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81 (1996) 4313-4317
121. Hernandez C., Lecube A., Barbera G., Chacon P., Lima J., and Simo R. Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men. Med Sci Monit 9 (2003) CR114-CR119
122. Sampietro T., Tuoni M., Ferdeghini M., et al. Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia. Circulation 96 (1997) 1381-1385
123. Paiker J.E., Raal F.J., Veller M., von Arb M., Chetty N., and Naran N.H. Cell adhesion molecules-can they be used to predict coronary artery disease in patients with familial hypercholesterolaemia?. Clin Chim Acta 293 (2000) 105-113
124. Hackman A., Abe Y., Insull W.J., et al. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 93 (1996) 1138-1334
125. Blann A.D., and Lip G.Y.H. Cell adhesion molecules in cardiovascular disease: what can soluble levels tell us?. Heart 81 (1999) 101-102
126. Gearing A.J.H., and Newman W. Circulating adhesion molecules in disease. Immunol Today 14 (1993) 506-512
127. Schonbeck U., and Libby P. CD40 signaling and plaque instability. Circ Res 89 (2001) 1092-1103
128. Ludewig B., Henn V., Schroder J.M., Graf D., and Kroczek R.A. Induction, regulation and function of soluble TRAP [CD40 ligand] during interaction of primary CD4+CD45RA+ T cells with dendritic cells. Eur J Immunol 26 (1996) 3137-3143
129. Urbich C., Dernbach E., Aicher A., Zeiher A.M., and Dimmeler S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 106 (2002) 981-986
130. Lutgens E., and Daemen M. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med 12 (2002) 27-32
131. Bavendiek U., Libby P., Kilbride M., Reynolds R., Mackman N., and Schonbeck U. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor κB, and Egr-1. J Biol Chem 277 (2002) 25032-25039
132. Schonbeck U., Mach F., Sukhova G.K., et al. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol 156 (2000) 7-14
133. Inwald D.P., McDowall A., Peters M.J., Callard R.E., and Klein N.J. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 92 (2003) 1041-1048
134. Garlichs C.D., John S., Schmeiber A., et al. Upregulation of CD40 and CD40 ligand [CD154] in patients with moderate hypercholesterolemia. Circulation 104 (2001) 2395-2400
135. Aukrust P., Muller F., Ueland T., et al. Enhanced levels of soluble membrane bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100 (1999) 614-620
136. Schonbeck U., Varo N., Libby P., Buring J., and Ridker P.M. Soluble CD40L and cardiovascular risk in women. Circulation 104 (2001) 2266-2268
137. Schoenberger S.P., Toes R.E., van Der Voort E.I., Offringa R., and Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393 (1998) 480-483
138. Ahn E.R., Lander G., Jy W., et al. Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. Thromb Res 114 (2004) 143-148
139. Bereczi D., Nagy E., Pal A., Magyar M.T., and Balla J. Should soluble CD40 ligand be measured from serum or plasma samples?. Arterioscler Thromb Vasc Biol 23 (2003) 1129-1130
140. Blake G.J., Ostfeld R.J., Yucel E.K., et al. Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI. Arterioscler Thromb Vasc Biol 23 (2003) e11-e14
141. Tom J., Gilmore G., Yi Q., Hankey G.J., and Eikelboom J.W. Measurement of soluble CD40 ligand in serum and plasma (Letter to the Editor). J Thromb Haemost 2 (2004) 2067-2069
142. Tselepis A.D., and Chapman M.J. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A, platelet activating factor acetylhydrolase. Atheroscler Suppl 3 (2002) 57-68
143. Kume N., Cybulsky M.I., and Gimbrone M.A. Lysophosphatidylcholine: a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 90 (1992) 1138-1144
144. Blake G.J., Dada N., Fox J.C., Manson J.E., and Ridker P.M. A prospective evaluation of lipoprotein-associated phospholipase A[2] levels and risk of future cardiovascular events in women. J Am Coll Cardiol 38 (2001) 1302-1306
145. Blankenberg S., Stengel D., Rupprecht H.J., et al. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res 44 (2003) 1381-1386
146. Packard C.J., O'Reilly D.S., Caslake M.J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 343 (2000) 1148-1155
147. Moriarty P.M., and Gibson C.A. Effect of low-density lipoprotein apheresis on lipoprotein-associated phospholipase A2. Am J Cardiol 95 (2005) 1246-1247
148. Albert M.A., Glynn R.J., Wolfert R.L., and Ridker P.M. The effect of statin therapy on lipoprotein associated phospholipase A2 levels. Atherosclerosis 182 (2005) 193-198
149. Blann A.D., and Taberner D.A. A reliable marker of endothelial cell dysfunction: does it exist?. Br J Haematol 90 (1995) 244-248
150. Hamsten A., Blomback M., Wiman B., et al. Haemostatic function in myocardial infarction. Br Heart J 55 (1986) 58-66
151. Haines A.P., Howarth D., North W.B.S., et al. Haemostatic variables and the outcome of myocardial infarction. Thromb Haemost 50 (1983) 800-803
152. Lip G.Y.H., Lowe G.D.O., Metcalfe M.J., Rumley A., and Dunn F.G. Effects of warfarin therapy on plasma ibrinogen, von Willebrand factor and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms. Am J Cardiol 76 (1995) 453-458
153. Jansson J.H., Nilsson T.K., and Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 66 (1991) 351-355
154. Cortellaro M., Boschetti C., Cofrancesco E., et al. The PLAT study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Arterioscler Thromb 12 (1992) 1063-1070
155. Thompon S.G., Kienast J., Pyke S.D.M., Haverkate F., and van der Loo J.C.W. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 332 (1995) 635-641
156. Meade T.W., Cooper J.A., Stirling Y., Howarth D.J., Ruddock V., and Miller G.J. Factor VIII, ABO blood group and the incidence of ischemic heart disease. Br J Haematol 88 (1994) 601-607
157. Meade T.W., Mellows S., Brozovic M., et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park heart study. Lancet 2 (1986) 533-537
158. Montalescot G., Ankri A., Vicaut E., Drobinski G., Grosgogeat Y., and Thomas D. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation 92 (1995) 31-38
159. Smith F.B., Lowe G.D.O., Fowkes F.G., et al. Smoking, hemostatic factors and lipid peroxides in a population case-control study of peripheral arterial disease. Atherosclerosis 102 (1993) 155-162
160. Wooburn K.F., Rumley A., Pollock J.G., Quin R.O., and Lowe G.D. Prediction of outcome in infrainguinal bypass grafting. Br J Surg 80 (1993) 525-526
161. Fowkes F.G.R., Lowe G.D.O., Housley E., et al. Cross linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary artery disease. Lancet 342 (1993) 84-86
162. Gaede P., Vedel P., Parving H.H., and Pedersen O. Elevated levels of plasma von Willebrand factor and the risk of macro and microvascular disease in type 2 diabetic patients with microalbuminuria. Nephrol Dial Transplant 16 (2001) 2028-2033
163. Chaturvedi N., Fuller J.H., Pokras F., Rottiers R., Papazoglou N., and Aiello L.P. EUCLID Study Group. Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition. Diabet Med 18 (2001) 288-294
164. Feng D., Bursell S.E., Clermont A.C., et al. von Willebrand factor and retinal circulation in early-stage retinopathy of type 1 diabetes. Diabetes Care 23 (2000) 1694-1698
165. Karamanos B., Porta M., Songini M., et al. Different risk factors of microangiopathy in patients with type 1 diabetes mellitus of short versus long duration. The EURODIAB IDDM Complications Study. Diabetologia 43 (2000) 348-355
166. Veves A., Akbari C.M., Primavera J., et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 47 (1998) 457-463
167. Fioretto P., Stehouwer C.D., Mauer M., et al. Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure. Diabetologia 41 (1998) 233-236
168. Greaves M., Malia R.G., Goodfellow K., et al. Fibrinogen and von Willebrand factor in IDDM: relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate: the EURODIAB IDDM Complications Study. Diabetologia 40 (1997) 698-705
169. Zimmermann J., Schramm L., Wanner C., et al. Hemorheology, plasma protein composition and von Willebrand factor in type 1 diabetic nephropathy. Clin Nephrol 46 (1996) 230-236
170. Stehouwer C.D.A., Fischer H.R.A., van Kuij A.W.R., Polak B.C.P., and Donker A.J.M. Endothelial dysfunction precedes development of microalbuminuria in IDDM. Diabetes 44 (1995) 561-564
171. Jager A., van Hinsbergh, Kostense P.J., et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects. The Hoorn Study. Arterioscler Thromb Vasc Biol 19 (1999) 3071-3078
172. Blann A.D., Maxwell S.R., Burrows G., and Miller J.P. Antioxidants, von Willebrand factor and endothelial cell injury in hypercholesterolaemia and vascular disease. Atherosclerosis 116 2 (1995) 191-198
173. Davi G., Romano M., and Mezzetti A. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation 97 10 (1998 (Mar 17)) 953-957
174. Seligman B.G., Biolo A., Polanczyk C.A., Gross J.L., and Clausell N. Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care 23 9 (2000 (Sep)) 1395-1400
175. Bickel C., Rupprecht H.J., Blankenberg S., et al. Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 89 (2002) 901-908
176. Bickel C., Rupprecht H.J., Blankenberg S., et al. Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol 82 (2002) 25-31
177. Joukhadar C., Klein N., Prinz M., et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterstatins. Thromb Haemost 85 (2001) 47-51
178. Blann A.D., Gurney D., Hughes E., et al. Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory markers in subjects with peripheral artery disease. Am J Cardiol 88 (2001) 89-92
179. Malik J., Wichterle D., Melenovsky V., et al. von Willebrand factor and assessment of endothelial function. Cardiovasc Res 54 (2002) 193-194
180. Romano M., Mezzetti A., Marulli C., et al. Fluvastatin reduces lectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Investig Med 48 (2000) 183-189
181. Tan K., Janus E.D., and Lam K.S. Effects of fluvastatin on prothrombotic and fibrinolytic factors in type 2 diabetes mellitus. Am J Cardiol 84 (1999) 934-937
182. Bo M., Bonino F., Neirotti M., et al. Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs. Angiology 42 (1991) 106-113
183. Farrer M., Winocour P.H., Evans K., et al. Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures. Diabetes Res Clin Pract 23 (1994) 111-119
184. Seljeflot I., Tonstad S., Hjermann I., et al. Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis 162 (2002) 179-185
185. Wada H., Mori Y., Kaneko T., et al. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol 44 (1993) 112-116
186. Fogari R., Marasi G., Vanasia A., et al. Comparative study of acipimox and pravastatin in patients with combined hyperlipidemia. Int J Clin Pharmacol Ther 35 (1997) 61-64
187. Asberg A., Hartmann A., Fjeldsa E., et al. Atorvastatin improves endothelial function in renal-transplant recipients. Nephrol Dial Transplant 16 (2001) 1920-1924
188. Ambrosi P., Aillaud M.F., Habib G., et al. Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipients. Thromb Haemost 83 (2000) 46-48
189. Ural A.U., Yilmaz M.I., Avcu F., et al. Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet and coagulation system components. Int J Hematol 76 (2002) 279-283
190. Daugherty A., Dunn J.L., Rateri D.L., and Heinecke J.W. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94 (1994) 437-444
191. Klebanoff S.J. Myeloperoxidase. Proc Assoc Am Physicians 111 (1999) 383-389
192. Podrez E.A., Abu-Soud H.M., and Hazen S.L. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med 28 (2000) 1717-1725
193. Sugiyama S., Okada Y., Sukhova G.K., Virmani R., Heinecke J.W., and Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 158 (2001) 879-891
194. Kutter D., Devaquet P., Vanderstocken G., Paulus J.M., Marchal V., and Gothot A. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit?. Acta Haematol 104 (2000) 10-15
195. Brennan M.L., Penn M.S., van Lente F., et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl Med 349 (2003) 1595-1604
196. Baldus S., Heeschen C., Meinertz T., et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108 (2003) 1440-1445
197. Nikpoor B., Turecki G., Fournier P., Theroux P., and Rouleau G.A. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 142 (2001) 336-339
198. Pecoits-Filho R., Stenvinkel P., Marchlewska A., et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Inter, Suppl (2003) S172-S176
199. Zheng L., Nukura B., Brennan M.L., et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 114 (2004) 529-541
200. Bergt C., Pennathur S., Fu X., et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A 101 (2004) 13032-13037
201. Eiserich J.P., Baldus S., Brennan M.L., et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 296 (2002) 2391-2394
202. Kumar A.P., and Reynolds W.F. Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun 331 (2005) 442-451
203. Shishehbor M.H., Brennan M.L., Aviles R.J., et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108 (2003) 426-431
204. Werner-Felmayer G., Werner E.R., Fuchs D., et al. Pteridine biosynthesis in human endothelial cells. Impact on nitric oxide-mediated formation of cyclic GMP. J Biol Chem 268 (1993) 1842-1846
205. Gupta S., Fredericks S., Schwartzman R.A., Holt D.W., and Kaski J.C. Serum neopterin in acute coronary syndromes. Lancet 349 (1997) 1252-1253
206. van Haelst P.L., Liem A., van Boven A.J., et al. Usefulness of elevated neopterin and C-reactive protein levels in predicting cardiovascular events in patients with non-Q-wave myocardial infarction. Am J Cardiol 92 (2003) 1201-1203
207. Zouridakis E., Avanzas P., Arroyo-Espliguero R., Fredericks S., and Kaski J.C. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 110 (2004) 1747-1753
208. Avanzas P., Arroyo-Espliguero R., Quiles J., Roy D., and Kaski J.C. Elevated serum neopteri predicts future adverse cardiac events in patients with chronic stable angina pectoris. Eur Heart J 26 (2005) 457-463
209. Bellosta S., Via D., Canavesi M., et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18 (1998) 1671-1678
210. Weber C., Erl W., Weber K.S., and Weber P.C. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 30 (1997) 1212-1217
211. Colli S., Eligini S., Lalli M., Camera M., Paoletti R., and Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arteriorscler Thromb Vasc Biol 17 (1997) 265-272
212. Gottsater A., Anwaar I., Lind P., Matiasson I., and Lindgarde F. Increasing plasma fibrinogen, but unchanged levels of intra-platelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin. Blood Coagul Fibrinolysis 10 (1999) 133-140
213. van Haelst P.L., van Doormaal J.J., May J.F., Gans R.O., Crijns H.J., and Cohen Tervaert J.W. Secondary prevention with fluvastatin decreases levels of adhesion molecules, neopterin and C-reactive protein. Eur J Intern Med 12 (2001) 503-509
214. Higazi A.A., Lavi E., Bdeir K., et al. Defensins stimulates the binding of lipoprotein(a) to human vascular endothelial and smooth muscle cells. Blood 89 (1997) 4290-4298
215. Barnathan E.S., Raghunath P.N., Tomaszewski J.E., Ganz T., Cines D.B., and Higazi A. Immunohistochemical localization of defensin in human coronary vessels. Am J Pathol 150 (1997) 1009-1020
216. Bdeir K., Cane W., Canziani G., et al. Defensin promotes the binding of lipoprotein(a) to vascular matrix. Blood 94 (1999) 2007-2019
217. Higazi A.A., Nassar T., Ganz T., et al. The alpha-defensins stimulate proteoglycan-dependent catabolism of low-density lipoprotein by vascular cells: a new class of inflammatory apolipoprotein and a possible contributor to atherogenesis. Blood 96 (2000) 1393-1398
218. Nassar T., Akkawi S., Bar-Shavit R., et al. Human alpha-defensin regulates smooth muscle cell contraction: a role for low-density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. Blood (2002) 4026-4032
219. Higazi A.A., Ganz T., Kariko K., and Cines D.B. Defensin modulates tissue-type plasminogen activator and plasminogen binding to fibrin and endothelial cells. J Biol Chem 271 (1996) 17650-17655
220. Chavakis T., Cines D.B., Rhee J.S., et al. Regulation of neovascularization by human neutrophil peptides (alpha-defensins): a link between inflammation and angiogenesis. FASEB J 18 (2004) 1306-1308
221. Koczulla R., von Degenfeld G., Kupatt C., et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 111 (2003) 1665-1672
222. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Study (4S). Lancet 344 (1994) 1383-1389
223. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
224. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 (1995) 1301-1307
225. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 335 (1996) 1001-1009
226. Bonetti P.O., Lerman L.O., Napoli C., and Lerman A. Statin effects beyond lipid lowering-are they clinically relevant?. Eur Heart J 24 (2003) 225-248
227. Aviram M., Rosenblat M., Bisgaier C.L., and Newton R.S. Atorvastatin and genfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 138 (1998) 271-280
228. Yasanuri K., Maeda K., Minami M., and Yoshikawa J. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress. Arterioscler Thromb Vasc Biol 21 (2001) 937-942
229. Fukumoto Y., Libby P., Rabkin E., et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanable heritable hyperlipidemic rabbits. Circulation 103 (2001) 993-999
230. Sumi D., Hayashi T., Thakur N.K., et al. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects-the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis 155 (2001) 347-357
231. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
232. Lindmark E., and Siegbahn A. Tissue factor regulation and cytokine expression in monocyte-endothelial cell co-cultures. Effects of a statin, an ACE-inhibitor and a low-molecular-weight heparin. Thromb Res 108 (2002) 77-84
233. Ikeda U., Shimpo M., Ohki R., et al. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension 36 (2000) 318-325
234. Bellosta S., Via D., Canavesi M., et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18 (1998) 1671-1678
235. Balk E.M., Lau J., Goudas L.C., et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease. A systematic review. Ann Intern Med 139 (2003) 670-682
236. Musial J., Undas A., Gajewski P., Jankowski M., Sydor W., and Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 77 (2001) 247-253
237. Holm T., Andreassen A.K., Veland T., et al. Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am J Cardiol 87 (2001) 815-818
238. Bays H.E., Stein E.A., Shah A.K., Maccubbin D.L., Mitchel Y.B., and Mercuri M. Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. Am J Cardiol 90 (2002) 942-946
239. Bickel C., Rupprecht H.J., Blankenberg S., et al. Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol 82 (2002) 25-31
240. Nawawi H., Osman N.S., Yusoff K., and Khalid B.A. Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia. Horm Metab Res 35 (2003) 479-485
241. Ascer E., Bertolami M.C., Venturinelli M.L., et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 177 (2004) 161-166
242. Okopien B., Krysiak R., Kowalski J., et al. The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis 176 (2004) 327-335
243. Okopien B., Krysiak R., Haberka M., and Herman Z.S. Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary mixed dyslipidemia. J Cardiovasc Pharmacol 45 (2005) 314-320
244. Undas A., Celinska-Lowenhoff M., Domagala T.B., et al. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb Haemost 94 (2005) 193-199
245. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 3 (2003 (Jan 28)) 499-511
246. Pearson T.A., Mensah G.A., Hong Y., and Smith Jr. SC. CDC; AHA. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: overview. Circulation 110 25 (2004 (Dec 21)) e543-e544
247. Fortmann S.P., Ford E., Criqui M.H., et al. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: report from the population science discussion group. Circulation 110 25 (2004 (Dec 21)) e554-e559
248. Yusuf S., Hawken S., Ounpuu S., et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 9438 (2004 (Sep 11-17)) 937-952